Chimerix enters up to $180M license deal with SymBio Pharma for Brincidofovir
Chimerix announces an exclusive global license agreement with SymBio Pharmaceuticals, under which SymBio has exclusively licensed the worldwide rights to develop, manufacture and commercialize brincidofovir in all human indications, excluding the prevention and treatment of smallpox. Moving forward, SymBio will be responsible for all future development and commercialization as well as manufacturing costs associated with brincidofovir in the licensed indications. Under the terms of the agreement, Chimerix will receive an upfront payment of $5M plus potential clinical, regulatory and commercial milestones of up to $180M. In addition, Chimerix is eligible to receive double digit royalties on net sales of brincidofovir worldwide.